Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma
- 1 April 1999
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 340 (13) , 1046-1047
- https://doi.org/10.1056/nejm199904013401315
Abstract
Chemoprevention can prevent second primary cancers in patients with cancer,1 but the effect of secondary cancer prevention on absolute survival has not been established. In 1996 we reported in the Journal that oral administration of an acyclic retinoid for 12 months significantly reduced the incidence of second primary cancers in patients who had received curative treatment for hepatocellular carcinomas,2 but the effect on survival did not reach statistical significance after a median follow-up period of 38 months.Keywords
This publication has 4 references indexed in Scilit:
- Recent Advances in Chemoprevention of CancerScience, 1997
- Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in ChildrenNew England Journal of Medicine, 1997
- Prevention of Second Primary Tumors by an Acyclic Retinoid, Polyprenoic Acid, in Patients with Hepatocellular CarcinomaNew England Journal of Medicine, 1996
- Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosisPublished by Elsevier ,1995